Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
- Raised their own holding by 76%.
- Similar past buys beat the S&P 500 52% of the time (268 cases), above the 46% for all buys.
- Their past buys: 2 of 3 beat the S&P 500 over 90 days.
Reasons for caution
- None found in the data.
What happened after this filing
Insider Twins: past buys with the same traits
1 insider buying · no CEO or CFO · $250K–$1M · stock down 20%+ in 3 months
ICHR Nov 17, 2025 +224.6% vs S&PKLXE Mar 11, 2020 +152.2% vs S&PCSPI Dec 15, 2023 +130.2% vs S&PAVTX Apr 24, 2023 -100.3% vs S&PCTNT Jun 17, 2026 -98.6% vs S&PRUBI Jun 16, 2026 -87.1% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Peter Boneparth (a director) bought $300K of JBLU at about $3.00 on Oct 29, 2026, reported to the SEC on Nov 2, 2026. Buys like this beat the S&P 500 52% of the time since 2020, against 46% for all insider buys. We found 4 points that make it worth a closer look and 0 reasons for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the JBLU alerts below.
Get this week's insider report
The week's biggest insider buys, every new cluster buy and the stocks to watch, in one printable PDF. Plus the free Monday email.
Check your inbox to confirm, so you get next week's report too.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.